Recombinant Human AGXT Protein，His

AGXT, short for alanine-glyoxylate aminotransferase, is a crucial enzyme involved in the metabolism of glyoxylate to glycine in the liver, playing a significant role in preventing the accumulation of toxic metabolites. Mutations in the AGXT gene can lead to primary hyperoxaluria type 1 (PH1), a rare genetic disorder characterized by excessive oxalate production, resulting in kidney damage and increased risk of kidney stones. Current therapeutic strategies for PH1 include renal replacement therapies and liver transplantation, but these approaches do not address the underlying enzymatic deficiency. Consequently, the recombinant expression and purification of AGXT protein have gained attention as potential avenues for developing enzyme replacement therapies. Research efforts focus on optimizing the expression of AGXT in suitable host systems, such as bacteria or yeast, to produce functionally active enzyme with proper folding and catalytic activity. Furthermore, understanding the structure-function relationships of AGXT through techniques like X-ray crystallography and molecular dynamics simulations can enhance the design of small molecules or gene therapies aimed at correcting the malfunctioning enzyme. This research area presents a promising outlook for innovative treatments for PH1, potentially improving the quality of life for affected individuals by providing a targeted intervention that addresses the root cause of the disease.